Time Course of Activity Signs at SD-OCT High Frequency Intravitreal Ranibizumab Treatment in CNV Due to AMD
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to detect persisting or early new activity of choroidal
neovascularization (CNV) due to age related macular degeneration (AMD) during the first 12
months following the first ranibizumab dose at baseline as assessed by weekly high resolution
optical coherence tomography (OCT). Detection of persisting or new signs of CNV activity at
OCT triggers further ranibizumab treatments considering that any ranibizumab injections can
maximally be applied as often as 2-weekly.